论文部分内容阅读
目的 研究金属硫蛋白（ＭＴ）基因在上皮性卵巢肿瘤中的表达及临床意义。方法 采用ＳＡＢＣ免疫组化法，对７２例上皮性卵巢肿瘤中金属硫蛋白的表达进行检测。结果 恶性肿瘤、交界性肿瘤和良性肿瘤 ＭＴ的表达分别为 ６４． ４％、３０．０％和 １１．８％，恶性肿瘤、交界性肿瘤 ＭＴ的表达明显高于良性肿瘤（分别为Ｐ＜０．０１和Ｐ＜０．０５）。随肿瘤组织病理分级及临床分期的增高，ＭＴ的表达也增加（Ｐ＜０．０５）。ＭＴ高表达者的生存期明显缩短。结论ＭＴ参与了上皮性卵巢恶性肿瘤的发生与发展，并有可能成为一个判定预后的有效指标。
Objective To study the expression of metallothionein (MT) gene in epithelial ovarian tumors and its clinical significance. Methods SABC immunohistochemistry was used to detect the expression of metallothionein in 72 cases of epithelial ovarian tumors. Results The expression of MT in malignant tumors, borderline tumors and benign tumors was 64. 4%, 30.0% and 11.8% respectively. The expression of MT in borderline and malignant tumors was significantly higher than that in benign tumors (P <0.01 and P <0.05, respectively). With the increase of tumor grade and clinical stage, the expression of MT also increased (P <0.05). The survival of patients with high expression of MT was significantly shorter. Conclusion MT is involved in the occurrence and development of epithelial ovarian cancer and may be an effective indicator of prognosis.